Reply by Authors
Bibliographic record
Abstract
No AccessJournal of UrologyAdult Urology1 Nov 2021Reply by Authorsis a reply to letterEditorial CommentEditorial Comment Samuel Tremblay, Lily Summers-Trasiewicz, Frédéric Pouliot, Juanita M. Crook, Keyue Ding, Laurence Klotz, and Paul Toren Samuel TremblaySamuel Tremblay http://orcid.org/0000-0002-0982-655X Department of Surgery, Faculty of Medicine, Université Laval; Centre de recherche CHU de Québec-Université Laval, Oncology Division, Quebec City, Quebec, Canada More articles by this author , Lily Summers-TrasiewiczLily Summers-Trasiewicz Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada More articles by this author , Frédéric PouliotFrédéric Pouliot Department of Surgery, Faculty of Medicine, Université Laval; Centre de recherche CHU de Québec-Université Laval, Oncology Division, Quebec City, Quebec, Canada Financial interest and/or other relationship with TerSera, Astellas and Janssen. More articles by this author , Juanita M. CrookJuanita M. Crook http://orcid.org/0000-0003-0711-3318 Department of Surgery, Division of Radiation and Developmental Radiotherapeutics, University of British Columbia, BC Cancer Center for the Southern Interior, Kelowna, British Columbia, Canada More articles by this author , Keyue DingKeyue Ding Canadian Clinical Trials Group, Queen’s University, Kingston, Ontario, Canada More articles by this author , Laurence KlotzLaurence Klotz http://orcid.org/0000-0003-1001-2235 Department of Surgery, Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada More articles by this author , and Paul TorenPaul Toren ‡Correspondence: Université Laval, CHU de Québec-Université Laval Research Center, 10 McMahon, Room 0877, Québec, Québec , Canada, G1R 3S1 E-mail Address: [email protected] http://orcid.org/0000-0002-5762-5787 Department of Surgery, Faculty of Medicine, Université Laval; Centre de recherche CHU de Québec-Université Laval, Oncology Division, Quebec City, Quebec, Canada Financial interest and/or other relationship with AstraZeneca, Bayer, Bristol-Myers-Squibb Canada, Ferring, TerSera and Abbvie. More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001946.03AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Reply by Authors." The Journal of Urology, 206(5), p. 1176 Reference 1. : Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 2020; 382: 2187. Google Scholar © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of Urology12 Aug 2021Editorial CommentJournal of Urology12 Aug 2021Editorial Comment Volume 206Issue 5November 2021Page: 1176-1176 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Samuel Tremblay Department of Surgery, Faculty of Medicine, Université Laval; Centre de recherche CHU de Québec-Université Laval, Oncology Division, Quebec City, Quebec, Canada More articles by this author Lily Summers-Trasiewicz Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada More articles by this author Frédéric Pouliot Department of Surgery, Faculty of Medicine, Université Laval; Centre de recherche CHU de Québec-Université Laval, Oncology Division, Quebec City, Quebec, Canada Financial interest and/or other relationship with TerSera, Astellas and Janssen. More articles by this author Juanita M. Crook Department of Surgery, Division of Radiation and Developmental Radiotherapeutics, University of British Columbia, BC Cancer Center for the Southern Interior, Kelowna, British Columbia, Canada More articles by this author Keyue Ding Canadian Clinical Trials Group, Queen’s University, Kingston, Ontario, Canada More articles by this author Laurence Klotz Department of Surgery, Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada More articles by this author Paul Toren Department of Surgery, Faculty of Medicine, Université Laval; Centre de recherche CHU de Québec-Université Laval, Oncology Division, Quebec City, Quebec, Canada ‡Correspondence: Université Laval, CHU de Québec-Université Laval Research Center, 10 McMahon, Room 0877, Québec, Québec , Canada, G1R 3S1 E-mail Address: [email protected]c.ulaval.ca Financial interest and/or other relationship with AstraZeneca, Bayer, Bristol-Myers-Squibb Canada, Ferring, TerSera and Abbvie. More articles by this author Expand All Advertisement PDF downloadLoading ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.048 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.003 | 0.002 |
| Scholarly communication | 0.004 | 0.005 |
| Open science | 0.002 | 0.003 |
| Research integrity | 0.018 | 0.020 |
| Insufficient payload (model declined to judge) | 0.126 | 0.100 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".